Clinical Trial Detail

NCT ID NCT02521493
Title Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Children's Oncology Group
Indications

acute myeloid leukemia

Therapies

Etoposide

Thioguanine

Cytarabine

Asparaginase Erwinia chrysanthemi

mitoxantrone hydrochloride

Daunorubicin

Asparaginase

Age Groups: child

No variant requirements are available.